BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20810109)

  • 1. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
    Atherosclerosis; 2010 Nov; 213(1):218-24. PubMed ID: 20810109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
    Clin Nephrol; 2014 Feb; 81(2):75-85. PubMed ID: 24321183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
    Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
    Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Sharman JE; Coombes JS
    J Atheroscler Thromb; 2010 Mar; 17(3):235-41. PubMed ID: 20032570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Cardinal JW; Coombes JS
    Nephrol Dial Transplant; 2012 Jan; 27(1):182-9. PubMed ID: 21543653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
    J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
    Bianchi S; Bigazzi R; Caiazza A; Campese VM
    Am J Kidney Dis; 2003 Mar; 41(3):565-70. PubMed ID: 12612979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
    de Zeeuw D; Anzalone DA; Cain VA; Cressman MD; Heerspink HJ; Molitoris BA; Monyak JT; Parving HH; Remuzzi G; Sowers JR; Vidt DG
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):181-90. PubMed ID: 25660356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
    Neilipovitz DT; Bryson GL; Taljaard M
    Can J Anaesth; 2012 Jun; 59(6):527-37. PubMed ID: 22528165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
    Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
    Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
    McCarey DW; McInnes IB; Madhok R; Hampson R; Scherbakov O; Ford I; Capell HA; Sattar N
    Lancet; 2004 Jun; 363(9426):2015-21. PubMed ID: 15207950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.